Lupin Limited has informed the Exchange regarding 'Updates on Transfer of Company's API R&D Division and Over-the-Counter Consumer Healthcare Business on slump sale basis.'.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Midcap 150 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has informed the exchange about progress on the transfer of its API (Active Pharmaceutical Ingredient) R&D Division and its Over-the-Counter Consumer Healthcare Business on a slump sale basis. A slump sale means the two divisions are being sold as going concerns for a lump sum amount, rather than asset-by-asset. This is a strategic restructuring move by the pharma major to streamline its portfolio and sharpen focus on its core prescription generics business. Specific financial details such as the buyer, deal value, or completion timeline have not been disclosed in this filing.
Shareholders should expect a sharper focus on Lupin's core prescription generics business going forward, along with possible one-time accounting gains or losses from the divestment. The market reaction will depend on the eventual deal value and the identity of the buyer once disclosed.